POC(Point of Care) 분자진단 시장 보고서 : 제품 및 서비스별, 기술별, 용도별, 최종사용자별, 지역별(2025-2033년)

The global point of care molecular diagnostics market size reached USD 4.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.7 Billion by 2033, exhibiting a growth rate (CAGR) of 8.78% during 2025-2033. The increasing incidence of infectious diseases paired with rapid development in healthcare facilities is significantly driving the market growth.

Point-of-care (POC) molecular diagnostics refer to tests performed by physicians to diagnose and detect infectious diseases. It includes hematology, pregnancy, fertility, infectious diseases, urinalysis testing kits, and cardiometabolic and glucose monitoring devices. POC molecular diagnostics is widely used for identifying infectious agents, minimal residual disease, and gastrointestinal disorders, monitoring hemoglobin and fecal occult blood, and determining a patient's ability to metabolize a drug or drug class. These tests offer faster results, reduce complications associated with mistreatment, and improve infection control measures. As a result, POC molecular diagnostics finds extensive applications in hospitals, intensive care units (ICUs), research institutes, clinics, decentralized laboratories, and homecare facilities.

Point of Care Molecular Diagnostics Market Trends:

The increasing prevalence of infectious diseases across the globe is creating a positive outlook for the market. POC molecular diagnostic tests is a cost-effective solution widely used to manage infectious diseases, such as flu, tuberculosis, human immunodeficiency virus (HIV) infection, chlamydia, and hepatitis. Additionally, the rising demand for PCR test kits to effectively manage and control the spread of COVID-19 is acting as another growth-inducing factor. Furthermore, the adoption of miniaturization, nanotechnology, and microfluidics to develop low-cost, user-friendly, and highly sensitive molecular diagnostic tests is providing an impetus to the market growth. Moreover, the implementation of various government initiatives toward improving healthcare infrastructure and enhancing molecular diagnostic capabilities is positively influencing the market growth. Other factors, including rapid advancements in deoxyribonucleic acid (DNA) sequencing, rising awareness regarding advanced therapeutic and diagnostic tests, increasing geriatric population, and recent developments in cloud-connected POC diagnostic technologies, are anticipated to drive the market growth.

Key Market Segmentation:

Breakup by Product and Service:

• Assays and Kits
• Instruments and Analyzers
• Software and Services

Breakup by Technology:

• Polymerase Chain Reaction (PCR)
• Hybridization
• DNA sequencing
• Microarray
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Others

Breakup by Application:

• Infectious Diseases
• Oncology
• Hematology
• Prenatal Testing
• Endocrinology
• Others

Breakup by End User:

• Physicians' Offices
• Hospitals and ICUs
• Research Institutes
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, Binx Health Inc., Co-Diagnostics Inc., F. Hoffmann-La Roche Ltd, Gene STAT Molecular Diagnostics LLC, Hemocue AB (Danaher Corporation), Meridian Bioscience Inc., Molbio Diagnostics Private Limited, Quidel Corporation, Siemens Healthcare GmbH (Siemens AG), Thermo Fisher Scientific Inc. and Visby Medical Inc.

Key Questions Answered in This Report

• 1.What was the size of the global point of care molecular diagnostics market in 2024?
• 2.What is the expected growth rate of the global point of care molecular diagnostics market during 2025-2033?
• 3.What are the key factors driving the global point of care molecular diagnostics market?
• 4.What has been the impact of COVID-19 on the global point of care molecular diagnostics market?
• 5.What is the breakup of the global point of care molecular diagnostics market based on the product and service?
• 6.What is the breakup of the global point of care molecular diagnostics market based on the technology?
• 7.What is the breakup of the global point of care molecular diagnostics market based on application?
• 8.What are the key regions in the global point of care molecular diagnostics market?
• 9.Who are the key players/companies in the global point of care molecular diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Point of Care Molecular Diagnostics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product and Service

• 6.1 Assays and kits
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Instruments and Analyzers
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Software and Services
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Technology

• 7.1 Polymerase Chain Reaction (PCR)
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Hybridization
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 DNA sequencing
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Microarray
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Isothermal Nucleic Acid Amplification Technology (INAAT)
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by Application

• 8.1 Infectious Diseases
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Oncology
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Hematology
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Prenatal Testing
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Endocrinology
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Others
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast

9 Market Breakup by End User

• 9.1 Physicians' Offices
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Hospitals and ICUs
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Research Institutes
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Becton Dickinson and Company
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Binx Health Inc.
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 Co-Diagnostics Inc.
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
  • 15.3.5 F. Hoffmann-La Roche Ltd
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
  • 15.3.6 Gene STAT Molecular Diagnostics LLC
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Hemocue AB (Danaher Corporation)
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 Meridian Bioscience Inc.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Molbio Diagnostics Private Limited
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
  • 15.3.10 Quidel Corporation
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Siemens Healthcare GmbH (Siemens AG)
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis
  • 15.3.12 Thermo Fisher Scientific Inc.
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
    • 15.3.12.4 SWOT Analysis
  • 15.3.13 Visby Medical Inc.
    • 15.3.13.1 Company Overview
    • 15.3.13.2 Product Portfolio